ArticleFrontiers in immunology2026
Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2).
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.Biochemical Society transactions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma remains a malignancy with a dismal prognosis, characterized by a median overall survival of less than one year in the metastatic setting despite standard-of-care chemotherapy regimens like gemcitabine plus nab-paclitaxel. The PDAC tumor microenvironment is notoriously immunosuppressive, rendering single-agent immune checkpoint inhibitors largely ineffective. Stereotactic Body Radiotherapy has emerged as a potential strategy to induce immunogenic cell death and remodel the TME. Based on promising Phase II data demonstrating a 78.48% 6-month progression-free survival rate with the triplet combination of GnP, Serplulimab and SBRT, this Phase III trial aims to validate the efficacy of this "radio-immuno-chemotherapy" strategy. Methods: This prospective, randomized, open-label, multicenter Phase III study will enroll 198 patients with recurrent or metastatic PDAC who are naive to systemic therapy for advanced disease. Participants will be randomized (1:1) to the Experimental Group receiving Serplulimab (300 mg IV, Q3W) combined with Gemcitabine 1000 mg/m² + nab-Paclitaxel 125 mg/m², Days 1, 8, Q3W and SBRT (33-50 Gy/5 fractions) initiated in Cycle 2, or the Control Group receiving GnP alone. Outcomes: The primary endpoint is Overall Survival. Secondary endpoints include progression-free survival, Objective Response Rate, Disease Control Rate, and safety profiles assessed via NCI-CTCAE v5.0. Exploratory endpoints include cyclic multiplex tissue staining assays to evaluate immune spatial interactions. Discussion: This study addresses the critical unmet need in advanced PDAC by evaluating a mechanistic synergy between cytotoxic debulking, radiation-induced immune priming, and checkpoint blockade. If successful, this regimen could establish a new standard of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.